Company intelligence / Profile preview
AP Biosciences
Taipei, Taipei City, Taiwanapbioinc.com ↗
- Ownership
- Private
- Employees
- ~37
- Development stage
- Phase 3
01
Overview
AP Biosciences is currently conducting multiple clinical trials. AP402 has entered Phase 1/2 trials for HER2+ cancer patients as of April 2025. AP203 began Phase I trials in 2023. AP505/B1962 started Phase I trials in 2023. IBI302 is in Phase III trials for nAMD.
- Therapeutic areas
- OphthalmologyOncology
- Modalities
- Bispecific antibodiesMonoclonal antibodiesProtein drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Innovent (IBI302 licensed to Innovent)Tasly Pharmaceutical Group (AP505/B1962 licensed for China rights)
Beyond the preview
Go deeper on AP Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP Biosciences.